Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Collegium Pharmaceutical Inc (COLL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9988)・商品コード:DATA904C9988
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:51
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium’s other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Canton, Massachusetts, the US.

Collegium Pharmaceutical Inc (COLL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Collegium Pharma Raises USD50 Million in Venture Financing 13
Collegium Pharma Raises US$4 Million In Venture Financing 15
Collegium Pharma Raises US$22.5 Million In Series B Financing 16
Licensing Agreements 17
Collegium Pharma Enters into Licensing Agreement with Depomed 17
Equity Offering 18
Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18
Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19
Collegium Pharma Raises USD55 Million in Public Offering of Shares 21
Collegium Pharma Raises USD80 Million in IPO 23
Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25
Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26
Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27
Collegium Pharmaceutical Inc – Key Competitors 28
Collegium Pharmaceutical Inc – Key Employees 29
Collegium Pharmaceutical Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 08, 2018: Collegium reports second quarter financial results and provides corporate update 31
May 09, 2018: Collegium Reports First Quarter Financial Results and Provides Corporate Update 2018 33
Mar 07, 2018: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 2017 35
Nov 08, 2017: Collegium Announcers Third Quarter Financial Results and Provides Corporate Update 37
Aug 09, 2017: Collegium Reports Second Quarter Financial Results and Provides Corporate Update 39
May 10, 2017: Collegium Reports 2017 First Quarter Financial Results and Provides Corporate Update 41
Mar 09, 2017: Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update 42
Corporate Communications 43
Jul 10, 2018: Collegium Promotes Scott Dreyer To CCO 43
Jun 04, 2018: Collegium Promotes Joseph Ciaffoni To Chief Executive Officer 44
May 30, 2017: Collegium Announces the Appointment of Joseph Ciaffoni as Chief Operating Officer 45
Product News 46
06/08/2017: Collegium Announces Scientific Presentations at the 2017 International Conference on Opioids 46
06/01/2017: Collegium Announces Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients 47
04/03/2017: Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients 48
02/01/2017: Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER 49
Clinical Trials 50
Mar 16, 2017: Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting 50
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Collegium Pharma Raises USD50 Million in Venture Financing 13
Collegium Pharma Raises US$4 Million In Venture Financing 15
Collegium Pharma Raises US$22.5 Million In Series B Financing 16
Collegium Pharma Enters into Licensing Agreement with Depomed 17
Collegium Pharma Plans to Raise up to USD60 Million in Public Offering of Shares 18
Collegium Pharma Raises USD92 Million in Pubic Offering of Shares 19
Collegium Pharma Raises USD55 Million in Public Offering of Shares 21
Collegium Pharma Raises USD80 Million in IPO 23
Collegium Pharma Raises USD8 Million in Private Placement of Series C Preferred Stock 25
Collegium Pharma Raises USD0.9 Million in Second Tranche of Private Placement of Series C Preferred Stock 26
Collegium Pharma Raises USD3 Million in First Tranche of Private Placement of Series C Preferred Stock 27
Collegium Pharmaceutical Inc, Key Competitors 28
Collegium Pharmaceutical Inc, Key Employees 29
Collegium Pharmaceutical Inc, Subsidiaries 30

List of Figures
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Collegium Pharmaceutical Inc, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9988)販売に関する免責事項を必ずご確認ください。
★調査レポート[Collegium Pharmaceutical Inc (COLL):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆